FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C. 20549
-------------	------------

Check this box if no longer subject	STA
to Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(b).	

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Posner Christopher					2. Issuer Name and Ticker or Trading Symbol Cara Therapeutics, Inc. [CARA]										heck all a	hip of Reporti pplicable) ector	ng Pe	erson(s) to Is	
(Last) (First) (Middle) C/O CARA THERAPEUTICS, INC. 4 STAMFORD PLAZA, 107 ELM STREET, 9TH				3. Date of Earliest Transaction (Month/Day/Year) 03/03/2023									X Off be	cer (give title w) President and (Other (specify below)			
(Street) STAMF(6902 Zip)		4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Lir	ne) <mark>X</mark> Fo Fo	ridual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person				
		Table	I - No	n-Deriva	tive S	Secu	rities	Acq	uired	, Dis	posed of	, or E	Ben	efici	ally Ov	ned			
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da				Exec if any	Deemed ecution Date, ny inth/Day/Year)		3. 4. Securitie Transaction Code (Instr. 8) 5.					nd Sec Ben Owi	mount of urities eficially led Following	Forr (D)	m: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership			
									Code	v	Amount	(A) (D)		Price	Trar	Reported Transaction(s) (Instr. 3 and 4)			(Instr. 4)
Common	Stock			03/03/2	2023			S ⁽¹⁾		5,987	D \$9		\$9.7	L ⁽²⁾	176,383		D		
		Tal									osed of, convertib					ed			
1. Title of Derivative Security (Instr. 3)	ive Conversion Date y or Exercise (Month/Day/Year) Execution Date,		ion Date,	4. Transaction Code (Instr. 8)		5. Nu of Deriv Secu Acqu (A) o Dispo of (D) (Instr and 5	rities ired r osed) : 3, 4	Expirat (Month	6. Date Exercisable and Expiration Date (Month/Day/Year) Date Expiration Exercisable Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) Amount or Number of Title Shares		f g lnstr.	8. Price of Derivativ Security (Instr. 5)		ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	

Explanation of Responses:

- 1. This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$9.60 to \$9.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Remarks:

/s/Darren DeStefano, Attorney-in-Fact

03/07/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.